Reverse-mode activation of the
Na(+)/Ca(2+) exchanger (NCX) during reperfusion following
ischemia contributes to Ca(2+) overload and cardiomyocyte injury.
KB-R7943, a selective reverse-mode NCX inhibitor, reduces lethal
reperfusion injury under non-ischemic conditions. However, the effectiveness of this compound under ischemic conditions is unclear. In the present study, we studied the effects of
KB-R7943 in an animal model of
hyperlipidemia. We further assessed whether the K
ATP (+) channels are involved in potential protective mechanisms of
KB-R7943. Twelve rats were fed normal chow, while 48 animals were fed a high
cholesterol diet. The hearts from the control and hypercholesterolemic rats were subjected to 25 min of global
ischemia followed by a 120-min reperfusion. Before this, hearts from hypercholesterolemic rats either received no intervention (
cholesterol control group) or were pre-treated with 1 μM
KB-R7943 and 0.3 μM of K
ATP (+) blocker
glibenclamide or
glibenclamide alone. The
infarction sizes (
triphenyltetrazolium assay) were 35 ± 5.0 % in the control group, 46 ± 8.7 % in the
cholesterol control group (p < 0.05 vs. control group), 28.6 ± 3.3 % in the
KB-R7943 group (p < 0.05 vs.
cholesterol control group), 44 ± 5 % in the
KB-R7943 and
glibenclamide group, and 47 ± 8.5 % in the
glibenclamide group (p < 0.05 vs. control group). Further,
KB-R7943 attenuated the magnitude of cell apoptosis (p < 0.05 vs.
cholesterol control group). These beneficial effects were abolished by
glibenclamide. In conclusion, diet-induced
hypercholesterolemia enhances myocardial injury. Selective reverse-mode NCX inhibitor
KB-R7943 reduces the
infarction size and apoptosis in hyperlipidemic animals through the activation of K
ATP (+) channels.